National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Cephalosporins and ciprofloxacin are commonly used in the treatment of gram-negative bacilli infections. Third generation cephalosporins are first choice but expensive than ciprofloxacin. So there is a need to compare their susceptibility. To compare the susceptibility of gram-negative bacilli clinical isolates to cephalosporins and ciprofloxacin. Susceptibility of ESBL and AmpC producers to ciprofloxacin. Disk diffusion method performed on100 Gram negative bacilli isolates. Susceptibility to cefuroxime, cefotaxime, ceftazidime, ceftazidime with clavulanic acid, cefoxitin, cefepime and ciprofloxacin were tested. ESBL detected by>7mm zone with ceftazidime clavulanic acid than ceftazidime alone. AmpC detected by cefoxitin resistant and cefepime sensitive. Among 100 isolates, 8 isolates were ESBL producers and 5 isolates were AmpC producers out of which 4(50%) isolates of ESBL and 2 isolates of AmpC producers were ciprofloxacin susceptible. Ciprofloxacin showed a susceptibility of 54% in Pseudomonas,72% in E. coli, 29% in Klebsiella, 66% in Enterobacter, 80% in Citrobacter and complete resistance in Acinetobacter. Ciprofloxacin was found to be more active than the fourth generation cephalosporin cefepime against gram negative bacilli. Since ciprofloxacin are cheaper it reduces the treatment cost.
Citations |
 |
 |
 |
 |
